Julie Errington

The impact of p53 status on cellular sensitivity to antifolate drugs.

Xiaohong Lü, Julie Errington, Nicola J. Curtin et al. · PubMed · 2001 · 74 citations

P53 Status, Chemoprevention Strategy, Immunology +16

Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study

Gareth J. Veal, Michael Cole, Julie Errington et al. · Clinical Cancer Research · 2005 · 66 citations

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

Gareth J. Veal, Michael Cole, Girish Chinnaswamy et al. · European Journal of Cancer · 2016 · 59 citations · Full text

Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.

Gareth J. Veal, Cinara Dias, L Price et al. · PubMed · 2001 · 54 citations

Cisplatin Therapy, Oncology, Adduct Formation +14

Adaptive Dosing Approaches to the Individualization of 13- <i>Cis</i> -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

Gareth J. Veal, Julie Errington, Sophie E. Rowbotham et al. · Clinical Cancer Research · 2012 · 52 citations · Full text